Loading stock data…
$12.68-0.32 (-2.46%)
NeuroPace, Inc.
NeuroPace, Inc. in the Healthcare sector is trading at $12.68 with a market capitalization of $435M. Wall Street consensus targets $20.00 (10 analysts), implying a +57.7% move over the next 12 months. The stock is currently 35% below its 52-week high of $19.60, remaining 16.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.83M↑ | $22.07M↓ | $26.59M↓ | $27.35M↑ | $19.50M |
| Gross Profit | $18.91M↑ | $18.05M↓ | $20.58M↓ | $21.17M↑ | $16.21M |
| Operating Income | -$5.14M↑ | -$5.57M↓ | -$1.77M↑ | -$2.60M↑ | -$8.19M |
| Net Income | -$6.20M↑ | -$6.69M↓ | -$2.73M↑ | -$3.50M↑ | -$8.65M |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant fo...